Home › Bids
› Seamless Early-Stage Clinical Drug Development (Phase 1 to 2
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Open218 days leftHealthcaregrant
Nov 22, 2024
Nov 19, 2026 12:00 AM
Healthcare
grant
...
AI Summary
This grant opportunity seeks applications for seamless early-stage clinical drug development (Phase 1 to 2a) for novel therapeutic agents targeting Alzheimer's Disease (AD) and AD-related Dementias (ADRD). It requires a UG3/UH3 Clinical Trial.
Want the full details?
Sign up free to see the agency name, contact info, and the original bid posting link.